Article Text

Download PDFPDF
Biomarkers and atrial fibrillation: is it prime time yet?

Statistics from Altmetric.com

Footnotes

  • Contributors RM, DHL and PS were involved in generating the focus of the manuscript. RM drafted the manuscript. All authors reviewed and agreed to the manuscript as written.

  • Competing interests The University of Adelaide received fees for PS's services on the advisory board of Biosense-Webster, Medtronic, St Jude Medical, Sanofi-Aventis and Merck, Sharpe and Dohme. The University of Adelaide received fees for lectures provided by PS for Biosense-Webster, Medtronic, St Jude Medical, Boston Scientific, Merck, Sharpe and Dohme, Biotronik and Sanofi-Aventis. The University of Adelaide has received research funding from Medtronic, St Jude Medical, Boston Scientific, Biotronik and Sorin to support PS's research. RM is supported by the Leo J Mahar Lectureship from the University of Adelaide, Adelaide, Australia. DHL is supported by a Postdoctoral Fellowship from the National Health and Medical Research Council of Australia. PS is supported by a Practitioner Fellowship from the National Health and Medical Research Council of Australia and by the National Heart Foundation of Australia.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles